"Pharmaceutical Express" Astellas reached a $600 million partnership for the first domestic P...

December 14, 2020 / Medical Information At a Glance: 2020 National Health Care Catalog Negotiations Begin; Astellas Reachs Over $600 Million Partnership; Sanofi/GSK Delays COVID-19 Vaccine Program; First Domestic PARP Inhibitor Approved for Market; Ganley NASH Candidate Drug ASC42 Approved by FDA Fast Track; Coxing Pharmaceutical Landing Board ... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief 2020 National Health Care Catalog Negotiations began today, and the 2020 National Health Care Catalog Drug Negotiations began at the National People's Congress Convention Center in Xicheng District.
health-care talks could last until Thursday, according to staff at the scene.
may be talking about more than 80 varieties a day.
(National Health Insurance Administration) to open the first batch of national varieties renewal work recently, Hainan, Yunnan, Hubei and other provinces have opened the first batch of national varieties renewal work, Imatini, chlorosatan and other 11 varieties of nuclear volume and renewal work.
(Multi-Provincial Health Insurance Authority) Part 2 has reached a $600 million partnership with Astellas, a biotechnology company, and Astellas to announce a global licensing agreement for the research, development and commercialization of VET2-L2, a candidate for intravenous lysovirus, as well as a partnership to jointly develop another lysovirus therapy.
the terms of the agreement, Astellas will make an advance payment of $56 million and other payments to KaliVir.
addition, Astellas may pay $307 million for VET2-L2 and $271 million for development, regulatory and commercial mileage, respectively.
(Pharmaceutical Rubik's Cube) Coxing Pharmaceutical Landing Board Today, Koxing Pharmaceuticals listed on the Kotsing Board.
opened the day at 44.00 yuan, up 97% from the offering price, with a total market value of 8.149 billion yuan.
its core product recombinant protein drug recombinant human erythrene (Epding) sales revenue in the past three years was about 280 million yuan, 440 million yuan, 560 million yuan, respectively.
Henri Nico Doods, President and Head of Clinical Research and Development, and His Swiss Pharmaceuticals announced that Dr. Henri Nico Doods, currentLy Chairman of the Scientific Committee, will serve as President and Head of Clinical Research and Development.
that the company's main pipeline products HMI-115 antibodies have passed animal experiments and Phase I clinical human safety experiments.
(The Associated Press) Part 3 drug information Mercadon K drug treatment MSI-H-dMMR metastatic colorectal cancer was recommended by the European Union CHMP on December 11, Merca East announced that the European Medicines Agency CHMP on the new adaptation of K drug received positive advice, recommended the approval of Keytruda as a microsatellite highly unstable or mismatched repair defective colorectal cancer treatment for adult patients.
(Xinhua) -- Sanofi/GSK postponed the COVID-19 vaccine program on December 11, and Sanofi and GlaxoSmithKline announced that they had postponed their trials of the COVID-19 vaccine based on adjective recombinant proteins to improve the vaccine's immune response in older populations.
the results of the latest Phase 1/2 study showed a lower immune response response among older people receiving the vaccine.
two pharmaceutical companies believe this may be due to insufficient antigen concentrations.
(Sina Pharmaceutical News) Hengrui Pharmaceutical Fluorine Pali Capsules approved for domestic listing according to NMPA official website news, recently, NMPA through the priority review and approval process conditional approval of Hengrui Pharmaceuticals declared a class 1 innovative drug fluorine Pali capsules (commodity name: Ari) listed.
the drug as the first approved domestic PARP inhibitor.
(Sina Pharmaceutical News) Haisco cyclophenol injection approved by NMPA listing according to NMPA official website news, recently, NMPA through the priority review approval process approved Haisco declared a class of innovative drug cyclophenol injection (commodity name: Sisshuning) listed.
the drug is an innovative drug that Hesco has independently researched and owns, and is used for sedative sedatives in the endoscopy of the digestive tract.
(Sina Pharmaceutical News) Ganlai NASH candidate drug ASC42 by the U.S. FDA fast-track qualification today, Goliath Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Ganlai announced that the U.S. FDA granted its NASH candidate drug ASC42 fast-track qualification.
currently has no FDA-approved NASH drug.
it is understood that Ganley also has two clinically-staged drug candidates in its NASH pipeline, ASC40 and ASC41, respectively.
(AP) Bayda Pharmaceuticals Class 1 anti-cancer new drug BPI-43487 was approved clinically today, CDE clinical implied license shows that Bayda Pharmaceuticals independently developed a new class of new drug FGFR4 oral small molecule inhibitor BPI-43487 capsules approved clinically, intended for FGF19 amplification of liver cell carcinoma, bile dud cell carcinoma and other solid tumor treatment.
is not currently available.
(Insight Database) Green leaf pharmaceutical injection with acetic acid Gosherin slow release microcosm III clinical completion of the first patient into the group today, green leaf pharmaceutical independently developed innovative preparation injection with acetic acid gosherin slow release microchip (LY01005) in China to complete the first patients for breast cancer Phase III clinical study, for prostate cancer Phase III clinical progress smoothly.
addition, LY01005 has completed Phase I clinical work in the United States.
on December 13th, Junshi BioPD-1 Antibody Phase 3 research reached the main endpoint, Junshi Bio announced that the randomized, double-blind, placebo-controlled, multi-center Phase 3 clinical study of advanced non-small cell lung cancer treated by the company's own anti-PD-1 monoantigeno-anti-combination chemotherapy had reached the pre-set main research endpoint by IDMC.
will submit a listing application to NMPA in the near future.
(Pharmaceutical Mission) pioneering pharmaceutical psyruamine treatment COVID-19 clinical trial results on December 11, pioneering pharmaceutical industry announced that the ongoing clinical trial of psyruamine treatment COVID-19 clinical trial results show that psyruamine significantly reduced covid-19 patients hospitalization rate and severity rate, and has good safety.
(Agency)